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Laboratory Medicine, National Taiwan University Hospital, Taipei, TaiwanAbstractVery few studies have focused on the outcome and management of patients with a single sputum isolate of nontuberculous mycobacterium
(NTM) on initial examination. Patients with a single isolate of Mycobacterium avium complex (MAC), M. chelonae-abscessus, M. kansasii, or
M. fortuitum from at least three sputum samples collected within 1 month were retrospectively identiﬁed. Those with follow-up sputum
samples within 1 year were included in the analysis. Among the 202 patients included, M. fortuitum (n = 71, 35.1%) and MAC (n = 70,
34.7%) were the most common NTM species isolated, followed by M. chelonae-abscessus (n = 40, 19.8%) and M. kansasii (n = 21, 10.4%).
The mean clinical follow-up period was 26.2 months. Forty-four patients (21.8%) had subsequent positive cultures of the same NTM
species, while eight (4.0%) had bronchiectasis and developed NTM lung disease (NTM-LD). Neither patients without bronchiectasis nor
those with M. fortuitum subsequently developed NTM lung disease. Among bronchiectatic patients with NTM other than M. fortuitum, age
65 years (p 0.006, OR 32.13), malignancy (p 0.048, OR 14.35), and initial radiographic score >2 (p 0.027, OR 20.06) were associated
with subsequent NTM-LD. In all of the NTM patients, bronchiectasis (p <0.001, OR 5.46) and age 65 years (p 0.002, OR 3.29) were
signiﬁcantly associated with subsequent positive NTM culture. In patients with a single isolation of NTM from respiratory specimens, the
presence of bronchiectasis and younger age indicates higher risk of subsequent culture-positivity and NTM-LD. Single isolation of
M. fortuitum is of little clinical signiﬁcance. Other patients with NTM, younger age, and more severe radiographic pulmonary lesion also
warrant further attention.
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been an emerging disease worldwide over the past decade [1].Microbiol Infect 2015; 21: 250.e1–250.e7
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.08.025The difﬁculty in its management lies in making a deﬁnite diag-
nosis, because the isolation of NTM can mean either coloni-
zation or true disease [2–4]. In most circumstances, the
microbiologic criteria require positive culture results from two
separate expectorated sputum samples [4]. There are, how-
ever, instances in the clinical setting of a single sputum positivity
for NTM among multiple sputum samples. Single isolation of
NTM in respiratory specimens can be attributed to contami-
nation with environmental NTM and is often considered clini-
cally insigniﬁcant [5]. Yet, there are still concerns that singleious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Lee et al. NTM single sputum positivity 250.e2NTM isolation from sputum samples can be an early sign of
NTM-LD [5].
The 2007 American Thoracic Society (ATS)/Infectious Dis-
eases Society of American (IDSA) statement suggests repeating
the sputum smear for acid-fast bacilli and mycobacterial cul-
tures if the initial sputum samples results are nondiagnostic [4].
It is also suggested that patients suspected of having NTM-LD
but who do not meet the diagnostic criteria be followed-up
until the diagnosis is ﬁrmly established or excluded [4]. While
repeating excessive sputum examinations is often time and la-
bor consuming, as well as expensive, the optimal duration of
follow-up is also undetermined. Although diagnostic pro-
cedures such as bronchoscopy are integrated in the ATS/IDSA
criteria, it is generally not considered due to its invasiveness and
potential risks [4]. Clinical parameters and predictors of NTM-
LD are therefore needed to help guide the management of
patients with single isolation of NTM from sputum samples.
Unfortunately, clinical studies on this topic are limited [5].
This study aimed to characterize patients with a single
isolation of NTM within multiple sputum samples and deter-
mine clinical factors predictive of NTM-LD in this group of
patients.Materials and methodsEthics statement
The Institutional Review Board of National Taiwan University
Hospital approved the study (NTUH REC: 201309019RIN).
The need for informed consent was waived because the
retrospective design did not add any risk to the participants.
Subjects
This study was conducted at the National Taiwan University
Hospital, a 2900-bed tertiary care center in northern Taiwan.
The mycobacterial laboratory registry database covering the
period of January 2007 to April 2012 was reviewed to identify
patients giving at least three expectorated sputum samples
within 1 month but with only a single isolate of NTM species,
which included Mycobacterium avium complex (MAC),
M. kansasii, M. chelonae-abscessus, and M. fortuitum. The selected
patients should also have at least one follow-up expectorated
sputum sample within the following year. Patients with active
pulmonary tuberculosis, recent active tuberculosis (within 6
months after complete treatment), or prior isolation of NTM
from respiratory specimens were excluded.
The clinical signiﬁcance of NTM isolates and the adequacy of
treatment were judged according to the guidelines established
by the ATS [4]. Accordingly, patients were considered as having
NTM-LD if they fulﬁlled the following criteria: (a) at least twoClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Insputum or one bronchial washing/brushing sample, or one lung
tissue culture positive for the same NTM species; (b) presence
of respiratory symptoms; (c) chest radiography or computed
tomography demonstrating new patch(es) of consolidation,
exudative, nodular inﬁltrates, cavitary lesions, or multi-focal
bronchiectasis; and (d) exclusion of other pulmonary causes
[4,6].
All respiratory specimens sent for mycobacterial culture
were processed as previously described [7]. Brieﬂy, NaOH-
citrate-N-acetyl-L-cysteine was added to each specimen in an
equal volume and allowed to settle at room temperature for 15
minutes. After centrifugation, the precipitate was re-suspended
in 1.5 mL phosphate-buffered saline (pH 7.4). Culture was
performed by inoculating 0.5 mL of sediment onto a Mid-
dlebrook 7H11 selective agar with antimicrobials (Remel, Inc.,
Lexena, KS, USA) and by using the ﬂuorometric BACTEC
technique (BACTEC MGIT 960 system; Becton-Dickinson
Diagnostic Instrument Systems, Sparks, MD, USA) as previ-
ously described [7,8].
Smears for acid-fast bacilli of the processed specimens were
stained with auramine-rhodamine ﬂuorochrome and examined
by standard procedures [7]. Fluorochrome stain-positive
smears were conﬁrmed by the Kinyoun stain method [7].
Mycobacterial species were identiﬁed by biochemical testing
[9]. Quality-control assessment of National Taiwan University
Hospital mycobacterial laboratory was periodically performed
by the National Reference Laboratory of the Centers for Dis-
ease Control of Taiwan [10].
Data collection
A standardized case record form was used to collect the de-
mographic and clinical data, including age, sex, diabetes mellitus,
cirrhosis, malignancy, chronic obstructive pulmonary disease,
asthma, prior history of pulmonary tuberculosis, radiographic
ﬁndings, and the course of anti-NTM treatment.
The number of sputum samples and interval between initial
and follow-up examination, as well as the period of clinical
follow-up, were recorded. The microbiology follow-up period
was deﬁned as the interval between the ﬁrst and last dates of
sputum culture in the same patient. The clinical follow-up
period was deﬁned as the interval between the time of ﬁrst
sputum examination and the time of last hospital visit by the
same patient.
Chest radiography and/or chest computed tomography
ﬁndings, including bronchiectasis, cavitation, consolidation, and
nodules/masses, were recorded. The deﬁnition of bronchiec-
tasis on images was based on previous criteria [11–13].
Radiographic severity was also judged according to previous
studies [14,15]. Brieﬂy, each lung was divided into three areas.
Each area was rated on a four-point scale of 0–3 for extent offectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 250.e1–250.e7
FIG. 1. The patient selection process. MAC, Mycobacterium avium
complex; M. che-abs, Mycobacterium chelonae-abscessus; NTM, non-
tuberculous mycobacteria; TB, tuberculosis.
250.e3 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIinﬁltration, with a maximum score of 18. The chest images
were initially interpreted by two experienced chest specialists.
In cases of discrepancy, the ﬁnal recording was made by
consensus.
Primary outcome was set as subsequent development of
NTM-LD. Secondary outcome was subsequent culture posi-
tivity for the same NTM species.
Statistical analysis
Proportions or means were used to describe the demographic,
clinical, and radiographic characteristics. Inter-group differences
were analyzed using independent-sampled t test for continuous
variables and χ2 test for categorical variables. Logistic regres-
sion analysis was used to identify factors associated with sub-
sequent NTM-LD and culture positivity for NTM on follow-up.
In the stepwise variable selection procedure, all of the potential
predictors were included. Signiﬁcance levels for entry and stay
were set at 0.15. A two-sided p <0.05 was considered signiﬁ-
cant. All analyses were performed using the SPSS v13.0 (SPSS,
Inc., Chicago, IL, USA).Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectResultsIn the patient selection process (Fig. 1), 260 persons with a
single isolate of NTM from sputum samples and at least one
follow-up sputum sample in the following year were identiﬁed
covering the study period of January 2007 to April 2012.
Twenty-three patients with active or recent pulmonary
tuberculosis were excluded, as well as 35 with prior isolate of
NTM from respiratory specimens and the single isolate of NTM
in the course of follow-up or treatment. A total of 202 patients
were enrolled for analysis.
Based on the demographic data of the 202 patients (Table 1),
their median age was 70 years, and there was male prepon-
derance (59%). Only one was a child (a 13-year-old boy) and
none was found to have cystic ﬁbrosis. M. fortuitum (n = 71,
35.1%) and MAC (n = 70, 34.7%) were the most common NTM
species isolated, followed by M. chelonae-abscessus (n = 40,
19.8%). The mean microbiology follow-up period was 12.0
months, but was signiﬁcantly shorter in the M. fortuitum group
(8.1 months). The mean clinical follow-up period was 26.2
months, with no signiﬁcant differences among groups. The most
common radiographic ﬁndings were bronchiectasis (n = 70,
35%), followed by consolidation (n = 35, 17%). A majority of
the patients had a radiographic score 2 (n = 127, 63%).
The initial culture-positive sputum samples were smear-
negative in all except one patient, an 80-year-old woman with
a single isolate of M. chelonae-abscessus. She was deemed as not
having NTM pulmonary disease, as judged by ATS criteria on
initial examination and during follow-up. Forty-four (21.8%)
patients had subsequent positive cultures, including 19 MAC, 12
M. fortuitum, 8 M. chelonae-abscessus, and 5 M. kansasii patients.
All of them had positive follow-up cultures within the ﬁrst year.
Among the 44 patients, the initial isolates were identical to the
follow-up isolates, while six of them also had mixed cultures at
follow-up. The co-cultured NTM isolates other than the initial
NTM, however, were neglected either because of the insigni-
ﬁcance of the species (e.g. M. gordonae) or minority in overall
cultures.
Of the 202 patients, 137 had no follow-up sputum samples
beyond 1 year (microbiology follow-up period 1 year) and the
other 65 did (microbiology follow-up period >1 year). Of the
latter, 43 were negative for follow-up cultures within and
beyond the ﬁrst year. The remaining 22 patients had positive
follow-up cultures within and beyond the ﬁrst year.
Of the 202 patients, eight developed NTM-LD on follow-up,
including six MAC, one M. chelonae-abscessus, and one
M. kansasii. The median interval between diagnosis of NTM-LD
and initial positive culture date was 4.5 months (range 1–23
months). Based on their characteristics, the eight (4.0%)ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 250.e1–250.e7
TABLE 1. Clinical characteristics of patients with a single isolation of NTM (n [ 202)
Characteristic
Total
(n [ 202)
MAC
(n [ 70)
M. che-abs
(n [ 40)
M. kansasii
(n [ 21)
M. fortuitum
(n [ 71)
Age 70 [13–99] 71 [32–93] 70 [48–89] 71 [45–99] 68 [13–93]
Male 120 (59%) 47 (67.1%) 21 (53%) 16 (76%) 36 (51%)
Number of sputum samples within 1 year 7.8 ± 3.5 8 ± 3.54 7.8 ± 3.8 7.4 ± 3.2 7.6 ± 3.3
Microbiology follow-up period, months 12.0 14.9 12.7 14.2 8.1
Clinical follow-up period, months 26.2 28.8 26.9 24.8 23.7
Presence of subsequent positive culture 44 (22%) 19 (27%) 8 (20%) 5 (24%) 12 (17%)
Diagnosed as NTM pulmonary disease 8 (4%) 6 (9%) 1 (3%) 1 (5%) 0
Age 57 [48–70] 57 [49–64] 48 70 NA
Male 5 (63%) 4 (67%) 0 1 (100%) NA
Months to 2nd positive cultures 2 [1–11] 1.5 [1–11] 2 6 NA
Months to diagnosis of NTM-LD (from single isolate of NTM) 4.5 [1–23] 2.5 [1–23] 7 6 NA
Microbiology follow-up months 22.5 [1–39] 17.5 [1–31] 39 16 NA
Clinical follow-up months 36 [12–60] 36 [12–60] 39 19 NA
Underlying disease
Old pulmonary tuberculosis 35 (17%) 15 (21%) 5 (13%) 5 (24%) 10 (14%)
Chronic obstructive pulmonary disease 35 (17%) 16 (23%) 4 (10%) 5 (24%) 10 (14%)
Malignancy 62 (31%) 24 (34%) 11 (28%) 5 (24%) 22 (31%)
Diabetes 36 (18%) 12 (17%) 9 (23%) 2 (10%) 13 (18%)
CKD (serum creatinine >2 mg/dL) 17 (8%) 7 (10%) 5 (13%) 0 5 (7%)
Radiographic ﬁndings
Bronchiectasis 70 (35%) 28 (40%) 10 (25%) 10 (48%) 22 (31%)
Cavitary 6 (8%) 1 (1%) 1 (2%) 2 (10%) 2 (3%)
Nodules 10 (14%) 2 (3%) 1 (3%) 3 (14%) 4 (6%)
Consolidation 35 (17%) 11 (16%) 13 (33%) 3 (14%) 8 (11%)
Radiographic score 2 127 (63%) 40 (57%) 24 (60%) 12 (57%) 51 (72%)
CKD, chronic kidney disease; LD, lung disease; MAC, Mycobacterium avium complex; M. che-abs, Mycobacterium chelonae-abscessus; NA, not available; NTM, nontuberculous
mycobacteria.
Data are mean ± SD, median [range], or number (%).
CMI Lee et al. NTM single sputum positivity 250.e4patients who subsequently developed NTM-LD were mainly
middle-aged adults. All except one (case 2) had subsequent
positive culture immediately on the next follow-up. The eight
NTM-LD patients were also judged by their primary care
physician to have NTM-LD. Among them, three had image
deterioration, two had symptoms progression, and three had
both image deterioration and symptoms progression.
None of the 71 patients in the M. fortuitum group had
another positive culture and subsequent NTM-LD, whereas
eight (6.1%) in the remaining 131 patients did (p 0.034, by χ2
test). Of the 131 patients, none of the 83 patients without
bronchiectasis developed NTM-LD during follow-up, compared
to eight (16.7%) of the remaining 48 patients who did (p 0.001,
by χ2 test). Thus, “M. fortuitum” was a signiﬁcant predictor of no
subsequent positive culture. Together with “no bronchiectasis,”
it was also a signiﬁcant predictor of nondevelopment of NTM-
LD.
Because neither nonbronchiectatic patients nor those with
M. fortuitum subsequently developed NTM-LD, only 48TABLE 2. Factors associated with subsequent NTM lung disease
positivity for NTM in all patients (n [ 202) with a single isolate
M. kansasii (n [ 48), by multivariate logistic regression analysis
Outcome Variables
Subsequent NTM lung disease Age: 65 vs. >65 years
Malignancy: Present vs. Absent
Initial radiographic score: >2 vs. 2
Subsequent culture-positivity for NTM Age: 65 vs. >65 years
Bronchiectasis: Present vs. Absent
NTM, nontuberculous mycobacteria.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inbronchiectatic patients with NTM species other than
M. fortuitum were included in the data in ﬁtting the logistic
regression model for the primary outcome of developing NTM-
LD. Age 65 years (p 0.006, OR 32.13), presence of malig-
nancy (p 0.048, OR 14.35), and initial radiographic score >2 (p
0.027, OR 20.06) were associated with subsequent NTM-LD
(Table 2).
Of the 202 patients with a single isolate of NTM, bronchi-
ectasis (p <0.001, OR 5.46) and age 65 years (p 0.002, OR
3.29) were signiﬁcant predictors of the secondary outcome
(subsequent positive cultures for NTM) (Table 2).DiscussionIn this study, 4.0% of patients with single sputum positivity for
NTM developed NTM-LD in a mean follow-up time of 12
months. Bronchiectasis was a strong predictor of subsequent
positive culture and NTM-LD among patients with singlein bronchiectatic patients (n [ 48) and subsequent culture
of Mycobacterium avium complex, M. chelonae-abscessus, or
Percent(s) of patients
developing outcome p OR (95% CI)
32% vs. 4% 0.006 32.13 (2.72–379.33)
30% vs. 13% 0.048 14.35 (1.02–201.13)
20% vs. 14% 0.027 20.06 (1.40–286.25)
33% vs. 15% 0.002 3.29 (1.56–6.92)
40% vs. 12% <0.001 5.46 (2.59–11.49)
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 250.e1–250.e7
250.e5 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIsputum positivity for MAC, M. chelonae-abscessus, and
M. kansasii. Younger age, malignancy, and higher radiographic
score were also associated with subsequent NTM-LD. Single
isolate of M. fortuitum from multiple sputum samples was of
little clinical signiﬁcance. The chance of subsequent sputum
positivity was low if follow-up sputum samples within 1 year
yielded no positive culture for the same NTM species.
In a previous study, only 2% of patients with a single isolate
of MAC developed radiologic evidence of disease and pro-
gression within 12 months of follow-up [16]. Another study
found that 14% of patients with a single sputum culture positive
for pathogenic NTM were diagnosed with NTM-LD within a
median follow-up period of 16 months [5]. These ﬁndings
suggest that a single isolation of NTM can be an early sign of
lung disease and patients can progress to lung disease in sub-
sequent follow-up [5]. Another possibility is that these patients
are under-diagnosed because they produce little sputum or
have inadequate skills for sputum collection [4,17]. Although
there is a chance of transient environmental exposure or lab-
oratory contamination causing a single NTM isolation, a certain
proportion of patients still demonstrate clinical deterioration
and are later diagnosed with NTM-LD [5,17]. The results of this
study were consistent with previous reports and remind phy-
sicians to be aware of possible clinical deterioration and
development of disease for patients with initial single sputum
isolate for NTM.
Bronchiectasis is considered an important underlying lung
disease contributing to NTM-LD [18,19]. Infections with NTM
have also been postulated to contribute to the initiation of
bronchiectasis [20], especially since the isolation of NTM is a
common ﬁnding among patients with bronchiectasis, with a
frequency reportedly up to 37% [13]. In fact, bronchiectasis
itself is even a radiographic characteristic integrated in the ATS
diagnostic criteria for NTM-LD [4]. The most common NTM
species isolated in patients with bronchiectasis is MAC. The
clinical signiﬁcance of NTM isolation among patients with
bronchiectasis remains debatable, with the exception that NTM
isolation in cystic ﬁbrosis bronchiectasis often indicates clinical
disease [21,22]. It is not surprising that bronchiectasis is the
single strongest factor predicting subsequent positive NTM
culture and NTM-LD. The present ﬁndings also indicate that
the colonization of NTM (one single positive culture) is less
likely to persist or even progress to lung disease in the absence
of structural lung conditions.
The ﬁnding that younger age is associated with a higher risk
of subsequent NTM-LD and subsequent positive cultures for
NTM is interesting. It can be hypothesized that this is partly
associated with greater functional impairment among older
patients [23]. Younger patients can have better expectoration
skills and the sputum samples are more adequate, thus lesseningClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthe risk of a false-negative result or contamination [24].
Furthermore, younger age is also a risk for greater decline in
lung function among patients with NTM isolates from respira-
tory specimens. Together with the present study, younger age
may be a prognostic factor predictive of faster clinical deteri-
oration among patients with NTM isolates [14,25].
Malignancy has also been proposed as a risk factor for NTM-
LD. The association is believed to be secondary to defective
cell-mediated immunity [26]. A higher radiographic score is also
associated with subsequent NTM-LD, probably reﬂecting a
greater severity of NTM colonization and thus, a higher risk of
clinical deterioration [14,27].
Six of the eight patients who developed subsequent NTM-LD
are MAC patients with bronchiectasis. This phenomenon may
also stem from the belief that MAC patients with nodular-
bronchiectatic type produce less or little sputum [17,28].
Initial sputum examinations can be a non-yielder for NTM in
this group of patients [28]. As such, a more aggressive
approach, like bronchoscopic examination with bronchial
washing or even trans-bronchial lung biopsy, may be considered
in this patient group if initial sputum results are inconclusive
[29].
M. fortuitum is considered less virulent. Its clinical signiﬁcance
in respiratory specimens is not well established, although it is
considered to cause colonization or transient infection in pa-
tients with underlying lung diseases [30]. Among patients with
two or more sputum specimens that are culture positive for
M. fortuitum, very few demonstrate clinical deterioration and
require antibiotic treatment [30]. Few studies also discuss the
clinical signiﬁcance of a single isolation of M. fortuitum. In the
present study, although patients with a single isolation of
M. fortuitum can have subsequent positive cultures, none were
further diagnosed as having M. fortuitum-LD. The clinical sig-
niﬁcance of a single isolation of M. fortuitum may therefore be
trivial.
The optimal follow-up duration for patients with a single
isolation of NTM remains unclear. In a previous study, 97% of
the ﬁrst two positive cultures grew from the initial three
sputum specimens [4]. In the study by Koh et al., 14% of pa-
tients with a single isolation of NTM had subsequent NTM
isolation and were diagnosed with NTM-LD [5]. The median
duration of the ﬁrst sputum culture to the second sputum
culture was 30 months (interquartile range 15–46 months) [5].
In the 65 patients with follow-up sputum samples with an in-
terval for more than 1 year of follow-up in the present study,
one-third had subsequent positive sputum and all within 1 year.
Nonetheless, 43 patients remained negative for NTM. These
ﬁndings suggest that the chance of sputum positivity decreases
signiﬁcantly after 1 year. Lengthy follow-up with sputum ex-
aminations may not be cost effective.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 250.e1–250.e7
CMI Lee et al. NTM single sputum positivity 250.e6This study has its limitations, mainly due to its retrospective
design. Follow-up duration, imaging modalities, and timing of
sputum acid-fast smear and mycobacterial culture were not
standardized. Therefore, the incidence of NTM-LD is likely to
be underestimated and it is difﬁcult to know at which moment
patients began to have NTM-LD. We also did not perform
detailed species identiﬁcation on MAC and M. chelonae-absces-
sus. Nonetheless, this study intended to provide a simple
guideline to help clinicians cope with a frequently encountered
scenario. Detailed species results from molecular techniques,
while providing more information, are not readily available for
many physicians. Also, we did not include all NTM species in
our patient selection. MAC, M. chelonae-abscessus, M. kansasii,
and M. fortuitum, however, are the most common NTM species
with clinical signiﬁcance isolated in respiratory specimens in
Taiwan [2–4]. M. xenopi was not included due to its rarity in
our institute [2,3].
In conclusion, 4% of patients with a single isolation of NTM
from respiratory specimens subsequently develop NTM-LD.
Young patients with bronchiectasis, underlying malignancy,
and high radiographic score warrant further attention. Single
isolation of M. fortuitum may be of little clinical signiﬁcance. The
risks of subsequent lung disease decrease signiﬁcantly if the next
follow-up sputum examinations yield negative ﬁndings within 1
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